Filtered By:
Condition: Bleeding
Drug: Plavix
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 822 results found since Jan 2013.
Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials
Aimed to evaluate and compare the interactive effects of different antiplatelet or anticoagulation strategies in patients with chronic coronary syndromes (CCS) after percutaneous coronary intervention (PCI). Randomized controlled trials comparing different antiplatelet or anticoagulant strategies in patients with CCS after PCI were included. The primary outcomes were major adverse cardiovascular event (MACE), mortality, ischemic and bleeding events. Compared to aspirin alone, addition of prasugrel or ticagrelor to aspirin resulted in lower risk of myocardial infarction (MI) [odds ratio (OR): 0.38 (95% confidence interval 0...
Source: Frontiers in Pharmacology - September 30, 2022 Category: Drugs & Pharmacology Source Type: research
Verifynow P2Y12 PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study
ConclusionVerifynow P2Y12 PRU-guided modification of clopidogrel for ischemic stroke significantly improved or prevented recurrence at the 1-year follow-up. Our findings suggest that clopidogrel therapy based on the PRU cutoff value of 190 should be considered to improve outcomes.Trial RegistrationClinicalTrials.gov NCT02618265 (December 1, 2015).
Source: Neurology and Therapy - September 26, 2022 Category: Neurology Source Type: research
Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial
CONCLUSIONS: Lower BMI is associated with a higher risk of primary composite outcomes, which is primarily related to the events of all-cause death or major bleeding during chronic maintenance antiplatelet monotherapy after PCI with DES.PMID:36123011 | DOI:10.1253/circj.CJ-22-0344
Source: Circulation Journal - September 19, 2022 Category: Cardiology Authors: Ki-Bum Won Eun-Seok Shin Jeehoon Kang Han-Mo Yang Kyung Woo Park Kyoo-Rok Han Keon-Woong Moon Seok Kyu Oh Ung Kim Moo-Yong Rhee Doo-Il Kim Song-Yi Kim Sung-Yun Lee Jung-Kyu Han Bon-Kwon Koo Hyo-Soo Kim Source Type: research
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
Conclusions: In critically-ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality.PMID:36036760 | DOI:10.1161/CIRCULATIONAHA.122.061533
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Erin A Bohula David D Berg Mathew S Lopes Jean M Connors Iljal Babar Christopher F Barnett Sunit-Preet Chaudhry Amit Chopra Wilson Ginete Michael H Ieong Jason N Katz Edy Y Kim Julia F Kuder Emilio Mazza Dalton McLean Jarrod M Mosier Ari Moskowitz Sabina Source Type: research
Antiplatelet therapy after acute ischemic stroke or transient ischemic attack
Expert Rev Clin Pharmacol. 2022 Aug 27. doi: 10.1080/17512433.2022.2118713. Online ahead of print.ABSTRACTINTRODUCTION: Antiplatelet therapy is key to prevent recurrences in patients with an acute or prior non-cardioembolic stroke or transient ischemic attack (TIA). The narrow balance between the risks of ischemic recurrence and major bleeding is a relevant clinical dilemma.AREAS COVERED: This review covers the current evidence on antiplatelet therapy for patients with non-cardioembolic stroke or TIA. Randomized controlled trials of antithrombotic strategies of patients with these conditions were searched in Pubmed/Medline...
Source: Pharmacological Reviews - August 29, 2022 Category: Drugs & Pharmacology Authors: Lorenzo Scalia Dario Calderone Davide Capodanno Source Type: research
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
Conclusions: In critically-ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality.PMID:36036760 | DOI:10.1161/CIRCULATIONAHA.122.061533
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Erin A Bohula David D Berg Mathew S Lopes Jean M Connors Iljal Babar Christopher F Barnett Sunit-Preet Chaudhry Amit Chopra Wilson Ginete Michael H Ieong Jason N Katz Edy Y Kim Julia F Kuder Emilio Mazza Dalton McLean Jarrod M Mosier Ari Moskowitz Sabina Source Type: research
Antiplatelet therapy after acute ischemic stroke or transient ischemic attack
Expert Rev Clin Pharmacol. 2022 Aug 27. doi: 10.1080/17512433.2022.2118713. Online ahead of print.ABSTRACTINTRODUCTION: Antiplatelet therapy is key to prevent recurrences in patients with an acute or prior non-cardioembolic stroke or transient ischemic attack (TIA). The narrow balance between the risks of ischemic recurrence and major bleeding is a relevant clinical dilemma.AREAS COVERED: This review covers the current evidence on antiplatelet therapy for patients with non-cardioembolic stroke or TIA. Randomized controlled trials of antithrombotic strategies of patients with these conditions were searched in Pubmed/Medline...
Source: Expert Review of Clinical Pharmacology - August 29, 2022 Category: Drugs & Pharmacology Authors: Lorenzo Scalia Dario Calderone Davide Capodanno Source Type: research
O10 The necessity of monitoring platelet response and adjusting antiplatelet agents for endovascular treatment of unruptured intracranial aneurysms: a single-center, retrospective, cohort study
ConclusionActive monitoring and adjustment antiplatelet agents did not reduce ischemic complications in endovascular treatment; however, tended to reduce the ischemic complication, especially in flow diversion. Low-dose prasugrel may be feasible without increasing hemorrhage in the endovascular treatment of unruptured intracranial aneurysms.ReferencesLi W. Effect of Adjusted Antiplatelet Therapy on Preventing Ischemic Events after Stenting for Intracranial Aneurysms. Stroke. 2021 Dec;52(12):3815–3825. DOI: 10.1161/StrokeAHA.120.032989. EPUB 2021 SEP 20. PMID: 34538087.Hwang G. Standard vs Modified Antiplatelet Prepar...
Source: Journal of NeuroInterventional Surgery - August 29, 2022 Category: Neurosurgery Authors: Moon, E., Kwon, B., Song, Y., Lee, D., Park, J., Suh, D. Tags: 14th Congress of the European Society of Minimally Invasive Neurological Therapy 2022 Meeting Abstracts Source Type: research
Risk of bleeding complications per different perioperative antithrombotic regimes during carotid endarterectomy: a national registry analysis
CONCLUSION: The effectiveness and safety of DAPT did not differ from single antiplatelet therapy (SAPT) in patients undergoing CEA and needs further evaluation in prospective studies. Considering additional data from the literature and guideline recommendations DAPT should be started immediately after stroke until 30 days after CEA followed by SAPT, due to possible reduction in the risk of recurrency.PMID:36031046 | DOI:10.1016/j.ejvs.2022.08.020
Source: PubMed: Eur J Vasc Endovasc ... - August 28, 2022 Category: Surgery Authors: Simone Ja Donners Joost M Mekke Eline S van Hattum Raechel J Toorop Gert J de Borst Dutch Audit for Carotid Interventions (DACI) Collaborators Source Type: research
CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD)
CONCLUSION: The aim of the GENPAD study is to evaluate the efficacy, safety, and cost-effectiveness of a genotype-guided antithrombotic treatment strategy compared to conventional clopidogrel treatment in PAD patients.PMID:35988587 | DOI:10.1016/j.ahj.2022.08.001
Source: Atherosclerosis - August 21, 2022 Category: Cardiology Authors: J Kranendonk L H Willems Rj van der Vijver-Coppen M Coenen E Adang R Donders C J Zeebregts Vhm Deneer Mmpj Reijnen C Kramers M C Warl é Source Type: research
Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials
ConclusionThe prognosis of patients with an ischemic stroke or transient ischemic attack is improved with antiplatelets. Cilostazol showed the best risk-benefit characteristics without trade-off with the risk of major bleeding. Improved stroke recurrence with intensified antiplatelet regimens is counterbalanced with higher bleeding risk, and consequently, mortality remains unaffected. Treatment decisions in stroke survivals should integrate the assessment of bleeding risk for better identification of patients with the highest benefit of treatment intensification. Systematic review registrationProspero registration number: ...
Source: PLoS One - August 17, 2022 Category: Biomedical Science Authors: D ániel Tornyos Source Type: research
